AN2 Therapeutics, Inc. (ANTX) stock
ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.55+0.11 (+2.48%)
Close on Nov 13, 2026Market cap $171.70MP/E –Yield –
AN2 Therapeutics total assets
Total assets on the balance sheet at the end of each period.
AN2 Therapeutics's total assets was $81.96M at Sep 30, 2026. For fiscal 2025 it was $61.95M, down 32.7% from the year before. The highest annual figure on record is $138.74M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.95M | -32.7% |
| FY2024 | Dec 31, 2024 | $92.09M | -33.6% |
| FY2023 | Dec 31, 2023 | $138.74M | +35.3% |
| FY2022 | Dec 31, 2022 | $102.56M | +57.0% |
| FY2021 | Dec 31, 2021 | $65.32M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $81.96M | +21.9% |
| Q2 FY2026 | Jun 30, 2026 | $81.68M | +7.7% |
| Q1 FY2026 | Mar 31, 2026 | $87.49M | +7.6% |
| Q4 FY2025 | Dec 31, 2025 | $61.95M | -32.7% |
| Q3 FY2025 | Sep 30, 2025 | $67.24M | -31.2% |
| Q2 FY2025 | Jun 30, 2025 | $75.83M | -30.1% |
| Q1 FY2025 | Mar 31, 2025 | $81.34M | -32.9% |
| Q4 FY2024 | Dec 31, 2024 | $92.09M | -33.6% |
| Q3 FY2024 | Sep 30, 2024 | $97.69M | -36.5% |
| Q2 FY2024 | Jun 30, 2024 | $108.48M | +9.7% |
| Q1 FY2024 | Mar 31, 2024 | $121.26M | +33.1% |
| Q4 FY2023 | Dec 31, 2023 | $138.74M | +35.3% |
| Q3 FY2023 | Sep 30, 2023 | $153.81M | +39.8% |
| Q2 FY2023 | Jun 30, 2023 | $98.93M | -17.6% |
| Q1 FY2023 | Mar 31, 2023 | $91.08M | -24.4% |
| Q4 FY2022 | Dec 31, 2022 | $102.56M | +57.0% |
| Q3 FY2022 | Sep 30, 2022 | $110.01M | – |
| Q2 FY2022 | Jun 30, 2022 | $120.02M | – |
| Q1 FY2022 | Mar 31, 2022 | $120.50M | – |
| Q4 FY2021 | Dec 31, 2021 | $65.32M | – |
See a number that looks wrong?